Global Psoriatic Arthritis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type of Molecule;
Biologics and Small Molecules.By Drug Class;
Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), and Others.By Route Of Administration;
Oral, Parenteral, and Topical.By Dosage Form;
Solid, Liquid and Semi-solid.By Distribuation Channel;
Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Psoriatic Arthritis Market (USD Million), 2021 - 2031
In the year 2024, the Global Psoriatic Arthritis Market was valued at USD 13,160.22 million. The size of this market is expected to increase to USD 21,691.68 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.
The global psoriatic arthritis market is witnessing significant growth driven by several factors, including the increasing prevalence of psoriasis, rising awareness and diagnosis of psoriatic arthritis, and advancements in treatment options. Psoriatic arthritis is a chronic inflammatory condition that affects joints and is often associated with psoriasis, a skin disorder. As the prevalence of psoriasis continues to rise globally, the incidence of psoriatic arthritis is also increasing, driving demand for effective treatment options to manage symptoms and improve patients' quality of life.
Advancements in treatment modalities have transformed the management of psoriatic arthritis, offering patients a range of therapeutic options to alleviate symptoms and prevent disease progression. Traditional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) have been supplemented by biologic agents and targeted synthetic DMARDs, which specifically inhibit inflammatory pathways involved in psoriatic arthritis. These innovative therapies have demonstrated significant efficacy in reducing joint inflammation, preserving joint function, and improving patient-reported outcomes, fueling market growth.
Moreover, the expansion of the biosimilars market presents opportunities for cost-effective alternatives to branded biologic drugs used in the treatment of psoriatic arthritis. Biosimilars offer comparable efficacy and safety profiles to their reference products while providing more affordable treatment options for patients and healthcare systems. As biosimilar versions of key biologic agents become available, market competition is expected to increase, driving down treatment costs and expanding access to psoriatic arthritis therapies. Overall, with ongoing research and development efforts and the expansion of biosimilar options, the global psoriatic arthritis market is poised for continued growth in the coming years.
Global Psoriatic Arthritis Market Recent Developments
-
In 2023, the advent of Janus kinase (JAK) inhibitors and IL-17 inhibitors significantly impacted the market, providing enhanced therapeutic options. Market leaders like Eli Lilly leveraged this trend by introducing advanced formulations aimed at improving patient quality of life.
-
In 2022, Amgen's advancements in biosimilars for psoriatic arthritis allowed for cost-effective alternatives to conventional therapies, thereby increasing accessibility and creating growth opportunities, especially in emerging markets.
Segment Analysis
The Global Psoriatic Arthritis Market has been segmented by type of molecule, drug class, route of administration, dosage form, and distribution channel, each playing a significant role in shaping the overall treatment landscape. The type of molecule segment includes biologics, small molecules, and biosimilars. Biologics, which are designed to target specific immune system components involved in the pathogenesis of psoriatic arthritis, dominate the market. These include tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (JAK) inhibitors. As the understanding of the immunological basis of the disease advances, the market is witnessing the introduction of novel biologics, offering more targeted and effective treatment options. Small molecules, often used in combination with biologics, continue to gain traction, particularly for patients who are unable to access biologic treatments or experience side effects.
The drug class segmentation highlights the variety of therapeutic approaches available for managing psoriatic arthritis. TNF inhibitors, which have been the standard treatment for many years, continue to lead the market, followed by newer biologics targeting IL-12/23, IL-17, and JAK inhibitors. These biologic agents are particularly beneficial for patients with moderate to severe disease, providing significant relief from both the skin and joint symptoms of psoriatic arthritis. Additionally, traditional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, still play a role in managing milder forms of the disease, although their use is decreasing as more targeted therapies become available. The availability of oral therapies alongside biologics has provided more treatment flexibility for patients, further driving growth in this segment.
The route of administration segmentation of the psoriatic arthritis market includes subcutaneous injections, intravenous infusions, and oral medications. Subcutaneous injections, typically used for biologics, are the most common route of administration for psoriatic arthritis treatments. Intravenous infusions, which are used for certain biologics and other targeted therapies, are generally administered in clinical settings and are particularly useful for patients with severe disease. Oral medications, including traditional DMARDs and newer small molecules, provide a more convenient option for patients and are growing in popularity due to their ease of use and ability to be taken at home. This variety in routes of administration offers patients flexibility in their treatment choices and is likely to remain a significant driver of market growth.
The dosage form segmentation includes injectable, oral, and topical formulations, with injectable biologics leading the market due to their efficacy in treating moderate to severe psoriatic arthritis. Oral formulations, particularly small molecules and traditional DMARDs, are expected to see an increase in demand, as they offer more convenient, less invasive options for patients. Topical formulations, while less commonly used for psoriatic arthritis compared to psoriasis, are still relevant for patients with mild symptoms. The distribution channel segmentation reveals the key role of hospitals, clinics, pharmacies, and e-commerce platforms in the delivery of treatments. Hospitals and clinics are vital for administering injectable biologics and intravenous infusions, while pharmacies and e-commerce platforms provide patients with access to oral medications and over-the-counter treatments. As the market expands, these channels will continue to adapt to the growing demand for psoriatic arthritis treatments, ensuring that patients have access to the most appropriate therapies for their condition.
Global Psoriatic Arthritis Segment Analysis
In this report, the Global Psoriatic Arthritis Market has been segmented by Type of Molecule, Drug Class, Route Of Administration, Dosage Form, Distribuation Channel and Geography.
Global Psoriatic Arthritis Market, Segmentation by Type of Molecule
The Global Psoriatic Arthritis Market has been segmented by Type of Molecule into Biologics and Small molecules.
The global psoriatic arthritis market has been segmented by type of molecule into biologics and small molecules, each offering distinct therapeutic approaches for managing the condition. Biologics, including monoclonal antibodies and fusion proteins, target specific components of the immune system involved in the inflammatory pathways of psoriatic arthritis. These biologic agents inhibit pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17), and interleukin-23 (IL-23), which play key roles in the pathogenesis of psoriatic arthritis. By blocking these inflammatory signals, biologics effectively reduce joint inflammation and slow disease progression, providing significant relief for patients with moderate to severe psoriatic arthritis.
In contrast, small molecules are synthetic compounds that modulate intracellular signaling pathways implicated in the inflammatory response of psoriatic arthritis. Small molecule inhibitors target specific enzymes or receptors involved in immune regulation, such as Janus kinase (JAK) inhibitors and phosphodiesterase-4 (PDE4) inhibitors. These oral medications interfere with intracellular signaling cascades, thereby suppressing the production of pro-inflammatory cytokines and dampening the inflammatory response in psoriatic arthritis. Small molecules offer the convenience of oral administration and may serve as alternative treatment options for patients who prefer non-injectable therapies or have contraindications to biologic agents.
The segmentation of the psoriatic arthritis market into biologics and small molecules reflects the diversity of treatment options available to patients, allowing healthcare providers to tailor therapy based on individual patient needs and preferences. While biologics have traditionally dominated the treatment landscape, the emergence of small molecule inhibitors offers additional therapeutic choices and expands the armamentarium for managing psoriatic arthritis. With ongoing research and development efforts focused on both biologics and small molecules, the global psoriatic arthritis market is poised for further innovation and advancements in treatment modalities, ultimately improving outcomes for patients with this chronic inflammatory condition.
Global Psoriatic Arthritis Market, Segmentation by Drug Class
The Global Psoriatic Arthritis Market has been segmented by Drug Class into Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), and Others.
NSAIDs are commonly used to manage the pain and inflammation associated with psoriatic arthritis, providing relief for patients with mild to moderate symptoms. These drugs, including ibuprofen and naproxen, help reduce inflammation but do not address the underlying immune system dysfunction driving the disease. NSAIDs are typically used in conjunction with other treatments and remain a foundational component in managing the early stages of psoriatic arthritis.
Non-biologic DMARDs, such as methotrexate, sulfasalazine, and leflunomide, are used to slow the progression of psoriatic arthritis by targeting the immune system. These drugs are commonly prescribed for patients with moderate disease activity who may not yet require biologic treatments. While effective in managing the disease, non-biologic DMARDs often take weeks or months to show their full effect and may cause side effects that require close monitoring. Despite the rise of biologic therapies, non-biologic DMARDs remain a key part of the treatment arsenal, especially in cases where biologics are not suitable or available.
Biologic DMARDs have transformed the treatment landscape for psoriatic arthritis by targeting specific molecules involved in the inflammatory process. These include tumor necrosis factor (TNF) inhibitors, interleukin inhibitors (such as IL-17 and IL-23 inhibitors), and Janus kinase (JAK) inhibitors. Biologics offer more targeted and effective options for patients with moderate to severe psoriatic arthritis, helping to control both skin and joint symptoms. The increasing availability of these biologics has led to improved treatment outcomes for patients, particularly for those who do not respond well to traditional DMARDs or NSAIDs. The growing use of biologic DMARDs is expected to drive significant market growth as more advanced therapies become available.
The "others" segment in the drug class category includes therapies that do not fall under traditional NSAIDs, non-biologic DMARDs, or biologic DMARDs. These can include newer oral small molecules or targeted therapies, corticosteroids for flare-ups, or other immunosuppressive agents. While less commonly used, these alternative therapies may play an important role in specific patient populations, particularly for those with refractory disease or those who experience adverse effects from standard treatments. As research continues into new therapeutic options, the "others" segment may expand to include additional promising treatments for psoriatic arthritis.
Global Psoriatic Arthritis Market, Segmentation by Route Of Administration
The Global Psoriatic Arthritis Market has been segmented by Route Of Administration into Oral, Parenteral, and Topical.
Oral administration is one of the most common routes, particularly for traditional disease-modifying antirheumatic drugs (DMARDs) and newer small molecules used in the treatment of psoriatic arthritis. These oral medications offer convenience and ease of use, allowing patients to take their treatments at home without the need for frequent medical visits. Drugs such as methotrexate, sulfasalazine, and JAK inhibitors are commonly administered orally, making this route a popular choice, especially for patients with milder forms of the disease or those who do not require biologic treatments.
Parenteral administration, which includes subcutaneous injections and intravenous infusions, is widely used for biologic therapies, particularly for patients with moderate to severe psoriatic arthritis. This route is preferred for biologic disease-modifying anti-rheumatic drugs (DMARDs), such as TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors, as these biologics are more effective when delivered directly into the bloodstream or tissues. Parenteral administration allows for higher bioavailability and faster action, which is critical for patients who need rapid symptom relief or disease-modifying effects. Subcutaneous injections are often self-administered by patients at home, while intravenous infusions are typically administered in a clinical setting.
Topical administration, while less commonly used for psoriatic arthritis compared to other routes, may still play a role in treating localized symptoms, especially when psoriatic arthritis is accompanied by skin lesions or psoriasis. Topical treatments include corticosteroids and other anti-inflammatory creams or gels that can be applied directly to affected areas. These treatments are typically used to alleviate joint discomfort or inflammation in milder cases or as a complementary therapy alongside other systemic treatments. However, topical treatments are not as effective in addressing the joint-specific symptoms of psoriatic arthritis and are generally considered a secondary option in more severe cases.
The segmentation of psoriatic arthritis treatment by route of administration reflects the diversity of options available to meet patients' varying needs. Oral medications are favored for ease of use, while parenteral biologics provide more effective disease control for those with moderate to severe cases. Topical treatments continue to serve a complementary role, particularly for skin symptoms. As the market for psoriatic arthritis treatments evolves, advancements in drug delivery methods may further influence these routes of administration, offering patients more options tailored to their disease severity and lifestyle.
Global Psoriatic Arthritis Market, Segmentation by Dosage Form
The Global Psoriatic Arthritis Market has been segmented by Dosage Form into Solid, Liquid and Semi-solid.
The segmentation of the global psoriatic arthritis market by dosage form into solid, liquid, and semi-solid formulations offers a nuanced understanding of patient preferences and treatment options. Solid dosage forms, such as tablets and capsules, remain a popular choice for oral medications used in the management of psoriatic arthritis. These formulations offer convenience, ease of administration, and precise dosing, making them widely accepted by patients and healthcare providers. Additionally, advancements in drug delivery technologies have led to the development of extended-release formulations, which provide sustained therapeutic effects and improve patient adherence to treatment regimens.
Liquid dosage forms, including solutions, suspensions, and syrups, offer alternative treatment options for patients with psoriatic arthritis, particularly those who may have difficulty swallowing solid oral medications. Liquid formulations provide flexibility in dosing and may be preferred by individuals who experience gastrointestinal issues or have specific dietary restrictions. Moreover, liquid medications allow for rapid absorption and onset of action, potentially improving treatment efficacy and patient outcomes in psoriatic arthritis management.
Semi-solid dosage forms, such as creams, gels, and ointments, are commonly used in the topical treatment of psoriatic arthritis-related skin manifestations, such as psoriasis plaques. These formulations provide localized delivery of active ingredients to affected areas, minimizing systemic exposure and reducing the risk of systemic side effects. Additionally, semi-solid formulations offer moisturizing properties, which can help alleviate dryness and irritation associated with psoriasis lesions, improving patient comfort and quality of life. Overall, the segmentation of the psoriatic arthritis market by dosage form reflects the diverse therapeutic landscape and the importance of tailoring treatment options to individual patient needs and preferences.
Global Psoriatic Arthritis Market, Segmentation by Distribuation Channel
The Global Psoriatic Arthritis Market has been segmented by Distribuation Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Hospital pharmacies are critical for patients who require more intensive or specialized care, including those receiving biologic therapies or intravenous infusions. These pharmacies are often located within hospital settings, where they provide medications that are typically prescribed by specialists and administered under medical supervision. Hospital pharmacies are particularly important for patients with severe cases of psoriatic arthritis who require advanced treatments, such as biologic DMARDs, which may need to be administered in a clinical setting for monitoring and safety reasons.
Retail pharmacies are another key distribution channel in the psoriatic arthritis market, serving as a primary point of access for patients with less severe forms of the disease or those who require ongoing management with oral medications or over-the-counter products. These pharmacies are easily accessible and play a significant role in the ongoing management of psoriatic arthritis by providing patients with traditional DMARDs, NSAIDs, and topical treatments. Retail pharmacies offer patients the convenience of picking up prescriptions in their local communities, and they often serve as the first line of contact for patients seeking advice or information about managing their condition.
Online pharmacies have emerged as an increasingly important distribution channel, driven by the growing trend of e-commerce and digital healthcare solutions. With the rise of home delivery services, online pharmacies offer patients the convenience of ordering their medications from the comfort of their homes. This is particularly appealing for individuals who may have mobility issues, live in remote areas, or prefer to avoid in-person visits to physical pharmacies. Online pharmacies also provide a wide range of products, including prescription medications and over-the-counter treatments, and often offer competitive pricing and convenience that attracts a broad customer base.
The segmentation of the psoriatic arthritis market by distribution channel underscores the evolving landscape of healthcare delivery. While hospital pharmacies remain essential for managing complex cases requiring specialist care, retail pharmacies provide widespread access to medications for general treatment. Online pharmacies, with their convenience and expanding reach, are playing an increasingly prominent role in the market, offering flexibility and convenience to patients managing their condition. As healthcare continues to digitize, the influence of online pharmacies is expected to grow, further shaping the way psoriatic arthritis treatments are distributed.
Global Psoriatic Arthritis Market, Segmentation by Geography
In this report, the Global Psoriatic Arthritis Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Psoriatic Arthritis Market Share (%), by Geographical Region, 2024
The global psoriatic arthritis market exhibits varying geographical distributions in terms of market share. North America, comprising the United States and Canada, commands a significant portion of the market share, owing to factors such as high disease prevalence, advanced healthcare infrastructure, and widespread adoption of biologic therapies. The region benefits from robust research and development activities, leading to the introduction of novel treatment options and ensuring a competitive market landscape. Additionally, favorable reimbursement policies and increasing healthcare expenditure contribute to the dominance of North America in the global psoriatic arthritis market.
Europe represents another prominent market for psoriatic arthritis treatment, accounting for a substantial share of the global market. Countries within the European Union, such as Germany, the United Kingdom, and France, exhibit strong demand for psoriatic arthritis therapies, driven by the growing prevalence of the condition and the availability of advanced treatment options. Moreover, the region boasts a well-established healthcare infrastructure, facilitating timely diagnosis and access to innovative therapies. However, market dynamics within Europe may vary between countries due to differences in healthcare policies, reimbursement frameworks, and patient demographics.
Asia Pacific is emerging as a rapidly growing market for psoriatic arthritis treatment, fueled by factors such as increasing disease awareness, rising healthcare expenditure, and expanding access to advanced medical care. Countries such as China, Japan, and India are witnessing a surge in psoriatic arthritis prevalence due to changing lifestyles, urbanization, and genetic predisposition. As a result, pharmaceutical companies are increasingly focusing on expanding their presence in the Asia Pacific region, introducing novel therapies and investing in research and development activities tailored to the unique needs of the local population. Despite the growing market potential, challenges such as regulatory hurdles and pricing pressures may impact market growth in certain Asia Pacific countries.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Psoriatic Arthritis Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Prevalence of Psoriasis
- Rising Awareness and Diagnosis of Psoriatic Arthritis
-
Advancements in Treatment Modalities - Advancements in treatment modalities are driving significant growth within the global psoriatic arthritis market. Traditionally, treatment options for psoriatic arthritis were limited to nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). However, the emergence of biologic agents and targeted synthetic DMARDs has revolutionized the management of psoriatic arthritis. These innovative therapies specifically target inflammatory pathways involved in the disease, providing more effective relief from symptoms such as joint pain, swelling, and stiffness.
Biologic agents, including tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (JAK) inhibitors, have demonstrated significant efficacy in reducing disease activity and slowing radiographic progression in patients with psoriatic arthritis. Additionally, targeted synthetic DMARDs, such as apremilast, inhibit specific enzymes involved in the inflammatory cascade, offering an oral treatment option with favorable safety and tolerability profiles. These advancements have expanded the treatment landscape for psoriatic arthritis, providing patients with more personalized and effective therapeutic options.
Ongoing research and development efforts are focused on exploring novel treatment modalities for psoriatic arthritis, including biologic agents targeting alternative inflammatory pathways and combination therapies with synergistic effects. Additionally, the integration of personalized medicine approaches, such as pharmacogenomics and biomarker-driven treatment algorithms, aims to optimize treatment selection and dosing strategies based on individual patient characteristics. As these advancements continue to evolve, the global psoriatic arthritis market is poised for further growth, with the potential to improve patient outcomes and quality of life.
Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
-
Stringent Regulatory Requirements - Stringent regulatory requirements pose a significant challenge in the global psoriatic arthritis market, impacting the development, approval, and commercialization of new therapies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose rigorous standards to ensure the safety, efficacy, and quality of pharmaceutical products. Meeting these requirements involves conducting extensive preclinical and clinical studies, which are time-consuming and resource-intensive. Additionally, regulatory agencies may require post-marketing surveillance and risk management plans to monitor the long-term safety and effectiveness of psoriatic arthritis treatments, further adding to the regulatory burden.
Navigating the complex regulatory landscape can delay the introduction of innovative therapies to the market, limiting treatment options for patients with psoriatic arthritis. Manufacturers must adhere to stringent guidelines for clinical trial design, data collection, and reporting, which may prolong the drug development process and increase associated costs. Additionally, variations in regulatory requirements across different geographic regions can complicate the global development and registration of psoriatic arthritis therapies, requiring companies to tailor their strategies to meet the specific demands of each regulatory authority.
Despite the challenges posed by stringent regulatory requirements, compliance is essential to ensure patient safety and maintain public trust in psoriatic arthritis treatments. Regulatory oversight plays a critical role in safeguarding the integrity of clinical trials, evaluating the benefits and risks of new therapies, and facilitating timely access to effective treatments for patients. Moreover, regulatory agencies may provide pathways for expedited review and approval of promising therapies, such as breakthrough designations or accelerated approval programs, which can accelerate the availability of innovative treatments for psoriatic arthritis patients. Ultimately, while navigating regulatory requirements may present obstacles for market participants, adherence to these standards is vital for advancing the development and accessibility of safe and efficacious therapies for psoriatic arthritis.
Opportunities
- Expansion of Biosimilars Market
- Personalized Medicine Approaches
-
Integration of Digital Health Technologies - Stringent regulatory requirements pose a significant challenge in the global psoriatic arthritis market, impacting the development, approval, and commercialization of new therapies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose rigorous standards to ensure the safety, efficacy, and quality of pharmaceutical products. Meeting these requirements involves conducting extensive preclinical and clinical studies, which are time-consuming and resource-intensive. Additionally, regulatory agencies may require post-marketing surveillance and risk management plans to monitor the long-term safety and effectiveness of psoriatic arthritis treatments, further adding to the regulatory burden.
Navigating the complex regulatory landscape can delay the introduction of innovative therapies to the market, limiting treatment options for patients with psoriatic arthritis. Manufacturers must adhere to stringent guidelines for clinical trial design, data collection, and reporting, which may prolong the drug development process and increase associated costs. Additionally, variations in regulatory requirements across different geographic regions can complicate the global development and registration of psoriatic arthritis therapies, requiring companies to tailor their strategies to meet the specific demands of each regulatory authority.
Despite the challenges posed by stringent regulatory requirements, compliance is essential to ensure patient safety and maintain public trust in psoriatic arthritis treatments. Regulatory oversight plays a critical role in safeguarding the integrity of clinical trials, evaluating the benefits and risks of new therapies, and facilitating timely access to effective treatments for patients. Moreover, regulatory agencies may provide pathways for expedited review and approval of promising therapies, such as breakthrough designations or accelerated approval programs, which can accelerate the availability of innovative treatments for psoriatic arthritis patients. Ultimately, while navigating regulatory requirements may present obstacles for market participants, adherence to these standards is vital for advancing the development and accessibility of safe and efficacious therapies for psoriatic arthritis.
Competitive Landscape Analysis
Key players in Global Psoriatic Arthritis Market include:
- AbbVie Inc.
- Amgen Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- UCB S.A.
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca PLC
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type of Molecule
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Dosage Form
- Market Snapshot, By Distribuation Channel
- Market Snapshot, By Region
- Global Psoriatic Arthritis Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Psoriasis
- Rising Awareness and Diagnosis of Psoriatic Arthritis
- Advancements in Treatment Modalities
- Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
- Stringent Regulatory Requirements
- Opportunities
- Expansion of Biosimilars Market
- Personalized Medicine Approaches
- Integration of Digital Health Technologies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Psoriatic Arthritis Market, By Type of Molecule, 2021 - 2031 (USD Million)
- Biologics
- Small molecules
- Global Psoriatic Arthritis Market, By Type of Molecule Drug Class, 2021 - 2031 (USD Million)
- Non-steroidal Anti-inflammatory Drugs (NSAIDS)
- Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Others
- Global Psoriatic Arthritis Market, By Type of Molecule Route Of Administration, 2021 - 2031 (USD Million)
- Oral
- Parenteral
- Topical
- Global Psoriatic Arthritis Market, By Dosage Form, 2021 - 2031 (USD Million)
- Solid
- Liquid
- Semi-solid
- Global Psoriatic Arthritis Market, By Type of Molecule Distribuation Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Psoriatic Arthritis Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Psoriatic Arthritis Market, By Type of Molecule, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Amgen Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- UCB S.A.
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca PLC
- Company Profiles
- Analyst Views
- Future Outlook of the Market